Abstract
Deimination refers to the conversion of protein-bound arginines into citrulline. It has been established as a posttranslational modification due to the lack of any known tRNA carrier for citrulline, as well as the presence of deiminases that are capable of catalyzing this modification in vitro. There is no known enzyme that can revert protein-bound citrulline into arginine, rendering it a relatively long-term modification. Elevated deimination has been found in neuronal tissues in a number of neurodegenerative diseases including multiple sclerosis and glaucoma. Observations in the retina, a tissue where the retinal ganglion cell layer lacks a substantial presence of astroglial cells, demonstrated that elevated and reduced deimination occurs simultaneously in astroglial cells and neurons, respectively. Such opposite effects are expected to complicate therapeutic strategies, necessitating cell-specific delivery systems for perturbation of deiminases that catalyze deimination in neuronal tissues. In this review, we will briefly discuss the occurrence of deimination with normal aging, the importance of deimination in diseases, and the effect of deimination on mRNA transport in neuronal tissue. Elevated deimination induces proteolysis via modification of protein structures, while reduced deimination affects protein synthesis and the outgrowth of dendrites in neurons.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Algeciras, M. E., Takahara, H., & Bhattacharya, S. K. (2008). Mechanical stretching elevates peptidyl arginine deiminase 2 expression in astrocytes. Current Eye Research, 33, 994–1001.
Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H., Coulson, A. R., Drouin, J., Eperon, I. C., Nierlich, D. P., Roe, B. A., Sanger, F., Schreier, P. H., Smith, A. J., Staden, R., & Young, I. G. (1981). Sequence and organization of the human mitochondrial genome. Nature, 290, 457–465.
Arnon, R., & Aharoni, R. (2007). Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders. Molecular Neurobiology, 36, 245–253.
Belogurov, A. A., Jr., Kurkova, I. N., Friboulet, A., Thomas, D., Misikov, V. K., Zakharova, M. Y., Suchkov, S. V., Kotov, S. V., Alehin, A. I., Avalle, B., Souslova, E. A., Morse, H. C., III, Gabibov, A. G., & Ponomarenko, N. A. (2008). Recognition and degradation of myelin basic protein peptides by serum autoantibodies: Novel biomarker for multiple sclerosis. Journal of Immunology, 180, 1258–1267.
Bhattacharya, S. K. (2009). Retinal deimination in aging and disease. IUBMB Life, 61, 504–509.
Bhattacharya, S. K., Crabb, J. S., Bonilha, V. L., Gu, X., Takahara, H., & Crabb, J. W. (2006a). Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis. Investigative Ophthalmology & Visual Science, 47, 2508–2514.
Bhattacharya, S. K., Crabb, J. S., Bonilha, V. L., Gu, X., Takahara, H., & Crabb, J. W. (2006b). Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis. Investigative Ophthalmology & Visual Science, 47, 2508–2514.
Bhattacharya, S. K., Sinicrope, B., Rayborn, M. E., Hollyfield, J. G., & Bonilha, V. L. (2008). Age-related reduction in retinal deimination levels in the F344BN rat. Aging Cell, 7, 441–444.
Bonilha, V. L. (2008). Age and disease-related structural changes in the retinal pigment epithelium. Clinical Ophthalmology, 2, 413–424.
Bonilha, V. L., Shadrach, K. G., Rayborn, M. E., Li, Y., Pauer, G. J., Hagstrom, S. A., Bhattacharya, S. K., & Hollyfield, J. G. (2013). Retinal deimination and PAD2 levels in retinas from donors with age-related macular degeneration (AMD). Experimental Eye Research, 111, 71–78.
Chou, S. M., Wang, H. S., & Komai, K. (1996). Colocalization of NOS and SOD1 in neurofilament accumulation within motor neurons of amyotrophic lateral sclerosis: An immunohistochemical study. Journal of Chemical Neuroanatomy, 10, 249–258.
Cuthbert, G. L., Daujat, S., Snowden, A. W., Erdjument-Bromage, H., Hagiwara, T., Yamada, M., Schneider, R., Gregory, P. D., Tempst, P., Bannister, A. J., & Kouzarides, T. (2004). Histone deimination antagonizes arginine methylation. Cell, 118, 545–553.
Ding, D., Enriquez-Algeciras, M., Dave, K. R., Perez-Pinzon, M., & Bhattacharya, S. K. (2012). The role of deimination in ATP5b mRNA transport in a transgenic mouse model of multiple sclerosis. EMBO Reports, 13, 230–236.
D’Souza, C. A., Wood, D. D., She, Y. M., & Moscarello, M. A. (2005). Autocatalytic cleavage of myelin basic protein: An alternative to molecular mimicry. Biochemistry, 44, 12905–12913.
Enriquez-Algeciras, M., Ding, D., Mastronardi, F. G., Marc, R. E., Porciatti, V., & Bhattacharya, S. K. (2013). Deimination restores inner retinal visual function in murine demyelinating disease. The Journal of Clinical Investigation, 123, 646–656.
Grant, J. E., Hu, J., Liu, T., Jain, M. R., Elkabes, S., & Li, H. (2007). Post-translational modifications in the rat lumbar spinal cord in experimental autoimmune encephalomyelitis. Journal of Proteome Research, 6, 2786–2791.
Hageman, G. S., Mullins, R. F., Russell, S. R., Johnson, L. V., & Anderson, D. H. (1999). Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB Journal, 13, 477–484.
Hageman, G. S., Luthert, P. J., Victor Chong, N. H., Johnson, L. V., Anderson, D. H., & Mullins, R. F. (2001). An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Progress in Retinal and Eye Research, 20, 705–732.
Heriot, W. J., Henkind, P., Bellhorn, R. W., & Burns, M. S. (1984). Choroidal neovascularization can digest Bruch’s membrane. A prior break is not essential. Ophthalmology, 91, 1603–1608.
Keilhoff, G., Prell, T., Langnaese, K., Mawrin, C., Simon, M., Fansa, H., & Nicholas, A. P. (2008). Expression pattern of peptidylarginine deiminase in rat and human Schwann cells. Developmental Neurobiology, 68, 101–114.
Lange, S., Gogel, S., Leung, K. Y., Vernay, B., Nicholas, A. P., Causey, C. P., Thompson, P. R., Greene, N. D., & Ferretti, P. (2011). Protein deiminases: New players in the developmentally regulated loss of neural regenerative ability. Developmental Biology, 355, 205–214.
Louw, C., Gordon, A., Johnston, N., Mollatt, C., Bradley, G., & Whiteley, C. G. (2007). Arginine deiminases: Therapeutic tools in the etiology and pathogenesis of Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 22, 121–126.
Maruyama, M., Higuchi, M., Takaki, Y., Matsuba, Y., Tanji, H., Nemoto, M., Tomita, N., Matsui, T., Iwata, N., Mizukami, H., Muramatsu, S., Ozawa, K., Saido, T. C., Arai, H., & Sasaki, H. (2005). Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer’s disease. Annals of Neurology, 57, 832–842.
Mastronardi, F. G., Ackerley, C. A., Arsenault, L., Roots, B. I., & Moscarello, M. A. (1993). Demyelination in a transgenic mouse: A model for multiple sclerosis. Journal of Neuroscience Research, 36, 315–324.
Mastronardi, F. G., Noor, A., Wood, D. D., Paton, T., & Moscarello, M. A. (2007). Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. Journal of Neuroscience Research, 85, 2006–2016.
Moscarello, M. A., Wood, D. D., Ackerley, C., & Boulias, C. (1994). Myelin in multiple sclerosis is developmentally immature. The Journal of Clinical Investigation, 94, 146–154.
Musse, A. A., Boggs, J. M., & Harauz, G. (2006). Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proceedings of the National Academy of Sciences of the United States of America, 103, 4422–4427.
Nair, A., Frederick, T. J., & Miller, S. D. (2008). Astrocytes in multiple sclerosis: A product of their environment. Cellular and Molecular Life Sciences, 65, 2702–2720.
Nakashima, K., Hagiwara, T., & Yamada, M. (2002). Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. The Journal of Biological Chemistry, 277, 49562–49568.
Nicholas, A. P., & Whitaker, J. N. (2002). Preparation of a monoclonal antibody to citrullinated epitopes: Its characterization and some applications to immunohistochemistry in human brain. Glia, 37, 328–336.
Nicholas, A. P., Sambandam, T., Echols, J. D., & Barnum, S. R. (2005). Expression of citrullinated proteins in murine experimental autoimmune encephalomyelitis. Journal of Comparative Neurology, 486, 254–266.
Nicholas, A. P., Lu, L., Heaven, M., Kadish, I., van Groen, T., Accaviti-Loper, M. A., Wewering, S., Kofskey, D., Gambetti, P., & Brenner, M. (2014). Ongoing studies of demination in neurodegenerative diseases using the F95 antibody. In A. P. Nicholas & S. K. Bhattacharya (Eds.), Protein deimination in human health and disease (pp. 257–280). New York: Springer.
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000). Multiple sclerosis. The New England Journal of Medicine, 343, 938–952.
Penfold, P., Killingsworth, M., & Sarks, S. (1984). An ultrastructural study of the role of leucocytes and fibroblasts in the breakdown of Bruch’s membrane. Australian Journal of Ophthalmology, 12, 23–31.
Pritzker, L. B., Joshi, S., Gowan, J. J., Harauz, G., & Moscarello, M. A. (2000). Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry, 39, 5374–5381.
Raijmakers, R., Zendman, A. J., Egberts, W. V., Vossenaar, E. R., Raats, J., Soede-Huijbregts, C., Rutjes, F. P., van Veelen, P. A., Drijfhout, J. W., & Pruijn, G. J. (2007). Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. Journal of Molecular Biology, 367, 1118–1129.
Rohrbach, A. S., Slade, D. J., Thompson, P. R., & Mowen, K. A. (2012). Activation of PAD4 in NET formation. Frontiers in Immunology, 3, 360.
Scofield, R. H. (2004). Autoantibodies as predictors of disease. Lancet, 363, 1544–1546.
Senshu, T., Sato, T., Inoue, T., Akiyama, K., & Asaga, H. (1992). Detection of citrulline residues in deiminated proteins on polyvinylidene difluoride membrane. Analytical Biochemistry, 203, 94–100.
Takahara, H., Kusubata, M., Tsuchida, M., Kohsaka, T., Tagami, S., & Sugawara, K. (1992). Expression of peptidylarginine deiminase in the uterine epithelial cells of mouse is dependent on estrogen. The Journal of Biological Chemistry, 267, 520–525.
Vossenaar, E. R., Zendman, A. J., van Venrooij, W. J., & Pruijn, G. J. (2003). PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. BioEssays, 25, 1106–1118.
Wang, Y., Wysocka, J., Sayegh, J., Lee, Y. H., Perlin, J. R., Leonelli, L., Sonbuchner, L. S., McDonald, C. H., Cook, R. G., Dou, Y., Roeder, R. G., Clarke, S., Stallcup, M. R., Allis, C. D., & Coonrod, S. A. (2004). Human PAD4 regulates histone arginine methylation levels via demethylimination. Science, 306, 279–283.
Wood, D. D., Ackerley, C. A., Brand, B., Zhang, L., Raijmakers, R., Mastronardi, F. G., & Moscarello, M. A. (2008). Myelin localization of peptidylarginine deiminases 2 and 4: Comparison of PAD2 and PAD4 activities. Laboratory Investigation, 88, 354–364.
Ziemssen, T. (2005). Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis. Journal of Neurology, 252(Suppl 5), 38–45.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Ding, D., Enriquez-Algeciras, M., Bhattacharya, S.K., Bonilha, V.L. (2017). Protein Deimination in Aging and Age-Related Diseases with Ocular Manifestations. In: Nicholas, A., Bhattacharya, S., Thompson, P. (eds) Protein Deimination in Human Health and Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-58244-3_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-58244-3_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-58243-6
Online ISBN: 978-3-319-58244-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)